SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 1, 2014--
Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the
final analysis of COMET-2, a randomized, double-blind, controlled trial
of cabozantinib in men with metastatic castration-resistant prostate
cancer (mCRPC) who are suffering from moderate to severe pain despite
optimized narcotic medication, and whose disease has progressed
following treatment with docetaxel as well as abiraterone and/or
enzalutamide. The trial did not meet its primary endpoint of alleviation
of bone pain, as determined by comparing the percentage of patients in
the two treatment arms who achieved a pain response at Week 6 that was
confirmed at Week 12 without increase in narcotic medication. Fifteen
percent of patients in the cabozantinib arm reported a pain response,
compared to 17 percent of patients in the control arm receiving
mitoxantrone/ prednisone. The difference in pain response between the
arms was not statistically significant. The safety profile of
cabozantinib in the trial was consistent with that observed in previous
studies in mCRPC.
“Following the COMET-1 top-line results announced in September, we
deprioritized the cabozantinib development program in mCRPC; at that
time, we also initiated a significant workforce reduction in order to
focus our development efforts and financial resources on the pivotal
phase 3 studies of cabozantinib in metastatic renal cell carcinoma (RCC)
and advanced hepatocellular carcinoma (HCC),” said Michael Morrissey,
Ph.D., president and chief executive officer of Exelixis. “With target
enrollment in the METEOR study in RCC recently achieved, we anticipate
top-line results in the second quarter of 2015. We also look forward to
Roche and Genentech’s continued regulatory progress with cobimetinib for
metastatic melanoma. The EU review is underway and the U.S. filing is
expected before year-end, which could ultimately lead to our opportunity
to co-promote cobimetinib in the U.S. if it is approved for this
indication.”
Exelixis will submit the results from the COMET program for potential
presentation at a future medical meeting.
About the COMET-2 Trial
COMET-2, the second phase 3 study from the COMET program, was a
randomized, double-blind, controlled trial designed to enroll patients
with CRPC that is metastatic to the bone, who were suffering from
moderate to severe pain despite optimized narcotic medication, and whose
disease had progressed following treatment with docetaxel as well as
abiraterone and/or enzalutamide. One hundred and nineteen of the planned
246 patients were randomized 1:1 to receive either cabozantinib or
mitoxantrone/prednisone. The primary endpoint was alleviation of bone
pain, as determined by comparing the percentage of patients in the two
treatment arms who achieve a pain response -- a greater than or equal to
30% decrease from baseline in the average of daily worst pain intensity
according to the BPI collected over seven days -- at Week 6 that is
confirmed at Week 12 without increase in narcotic medication. Secondary
endpoints were bone scan response and overall survival, and other
endpoints include PFS, safety, and evaluation of bone biomarkers and
circulating tumor cells.
About Cabozantinib
Cabozantinib inhibits the activity of tyrosine kinases including MET,
VEGFRs and RET. These receptor tyrosine kinases are involved in both
normal cellular function and in pathologic processes such as
oncogenesis, metastasis, tumor angiogenesis, and maintenance of the
tumor microenvironment.
COMETRIQ® (cabozantinib) is currently approved by the U.S. Food and Drug
Administration for the treatment of progressive, metastatic medullary
thyroid cancer (MTC).
The European Commission granted COMETRIQ conditional approval for the
treatment of adult patients with progressive, unresectable locally
advanced or metastatic MTC. Similar to another drug approved in this
setting, the approved indication states that for patients in whom
Rearranged during Transfection (RET) mutation status is not known or is
negative, a possible lower benefit should be taken into account before
individual treatment decisions.
Important Safety Information, including Boxed WARNINGS
WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE
-
Serious and sometimes fatal gastrointestinal perforations and
fistulas occur in COMETRIQ-treated patients.
-
Severe and sometimes fatal hemorrhage occurs in COMETRIQ-treated
patients.
-
COMETRIQ treatment results in an increase in thrombotic events, such
as heart attacks.
-
Wound complications have been reported with COMETRIQ.
-
COMETRIQ treatment results in an increase in hypertension.
-
Osteonecrosis of the jaw has been observed in COMETRIQ-treated
patients.
-
Palmar-Plantar Erythrodysesthesia Syndrome (PPES) occurs in patients
treated with COMETRIQ.
-
The kidneys can be adversely affected by COMETRIQ. Proteinuria and
nephrotic syndrome have been reported in patients receiving COMETRIQ.
-
Reversible Posterior Leukoencephalopathy Syndrome has been observed
with COMETRIQ.
-
Avoid administration of COMETRIQ with agents that are strong CYP3A4
inducers or inhibitors.
-
COMETRIQ is not recommended for use in patients with moderate or
severe hepatic impairment.
-
COMETRIQ can cause fetal harm when administered to a pregnant woman.
Adverse Reactions – The most commonly reported adverse drug reactions
(≥25%) are diarrhea, stomatitis, palmar-plantar erythrodysesthesia
syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue,
oral pain, hair color changes, dysgeusia, hypertension, abdominal pain,
and constipation. The most common laboratory abnormalities (≥25%) are
increased AST, increased ALT, lymphopenia, increased alkaline
phosphatase, hypocalcemia, neutropenia, thrombocytopenia,
hypophosphatemia, and hyperbilirubinemia.
Please see full U.S. prescribing information, including Boxed WARNINGS,
at www.COMETRIQ.com/downloads/Cometriq_Full_Prescribing_Information.pdf.
Please refer to the full European Summary of Product Characteristics for
full European Union prescribing information, including contraindication,
special warnings and precautions for use at www.sobi.com
once posted.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily on
COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple
receptor tyrosine kinases. Another Exelixis-discovered compound,
cobimetinib, a highly selective inhibitor of MEK, is being evaluated by
Roche and Genentech (a member of the Roche Group) in a broad development
program under a collaboration with Exelixis. For more information,
please visit the company's web site at www.exelixis.com.
Forward-Looking Statements
This press release contains forward-looking statements, including,
without limitation, statements related to: Exelixis’ plans to focus
financial resources on pivotal phase 3 studies of cabozantinib in RCC
and HCC; the continued development and clinical, therapeutic and
commercial potential of, and opportunities for, cabozantinib and
cobimetinib; anticipated developments and timing with respect to
Exelixis’ pivotal phase 3 study of cabozantinib in RCC; future
cobimetinib regulatory filings, regulatory progress and potential
approvals; the potential for Exelixis to co-promote cobimetinib in the
U.S. in metastatic melanoma; and future potential data presentations.
Words such as “focus,” “anticipate,” “look-forward,” “expected” “could,”
“will,” “potential,” or other similar expressions, identify
forward-looking statements, but the absence of these words does not
necessarily mean that a statement is not forward-looking. In addition,
any statements that refer to expectations or other characterizations of
future events or circumstances are forward-looking statements. These
forward-looking statements are based upon Exelixis’ current plans,
assumptions, beliefs, expectations, estimates and projections.
Forward-looking statements involve risks and uncertainties. Exelixis’
actual results and the timing of events could differ materially from
those anticipated in the forward-looking statements as a result of these
risks and uncertainties, which include, without limitation: risks
related to the potential failure of cabozantinib to demonstrate safety
and efficacy in clinical study; the availability of data at the expected
times; the clinical, therapeutic and commercial value of cabozantinib
and cobimetinib; Exelixis’ ability to conduct clinical trials of
cabozantinib sufficient to achieve a positive completion; risks and
uncertainties related to regulatory review and approval processes and
Exelixis’ compliance with applicable legal and regulatory requirements;
the general sufficiency of Exelixis’ capital and other resources and the
specific risk of unforeseen expenses that could diminish Exelixis’
financial ability to support its operations through the release of
top-line METEOR results; the uncertain timing and level of expenses
associated with the development of cabozantinib; risks related to
Exelixis’ ability to implement the referenced workforce reduction
according to plan and its impact on Exelixis’ business; market
competition; and other factors discussed under the caption “Risk
Factors” in Exelixis’ quarterly report on Form 10-Q filed with the
Securities and Exchange Commission (SEC) on November 4, 2014 and
in Exelixis' other filings with the SEC. The forward-looking statements
made in this press release speak only as of the date of this press
release. Exelixis expressly disclaims any duty, obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Exelixis' expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
trademarks.
Source: Exelixis, Inc.
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor
Relations and
Corporate Communications
shubbard@exelixis.com